APO Research, Inc.

APO RESEARCH · REPORT

Chronic Idiopathic Constipation (CIC) Drugs

Selected research

Industry Research

Chronic Idiopathic Constipation (CIC) Drugs Industry Research Report 2026

Market perspective

The global Chronic Idiopathic Constipation (CIC) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Chronic Idiopathic Constipation (CIC) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Chronic Idiopathic Constipation (CIC) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Chronic Idiopathic Constipation (CIC) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Chronic Idiopathic Constipation (CIC) Drugs include Sanofi, Pfizer, GlaxoSmithKline, Bayer, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Salix Pharmaceuticals, Roche Holding and Progenics Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Chronic Idiopathic Constipation (CIC) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Chronic Idiopathic Constipation (CIC) Drugs Market by Company

Sanofi

Pfizer

GlaxoSmithKline

Bayer

Synergy Pharmaceuticals

Sucampo Pharmaceuticals

Salix Pharmaceuticals

Roche Holding

Progenics Pharmaceuticals

Ironwood Pharmaceuticals

Ferring International Center

Chugai Pharmaceutical

Actavis

Chronic Idiopathic Constipation (CIC) Drugs Segment by Type

Lubiprostone

Linaclotide

Others

Chronic Idiopathic Constipation (CIC) Drugs Segment by Application

Ambulatory Surgical Centres

Hospitals & Clinics

Long Term Care Centres

Others

Chronic Idiopathic Constipation (CIC) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Idiopathic Constipation (CIC) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Idiopathic Constipation (CIC) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Idiopathic Constipation (CIC) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Chronic Idiopathic Constipation (CIC) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Chronic Idiopathic Constipation (CIC) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Chronic Idiopathic Constipation (CIC) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Chronic Idiopathic Constipation (CIC) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Chronic Idiopathic Constipation (CIC) Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Chronic Idiopathic Constipation (CIC) Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Product Type & Application Table 14. Global Chronic Idiopathic Constipation (CIC) Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Chronic Idiopathic Constipation (CIC) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 22. Sanofi Recent Developments Table 23. Pfizer Company Information Table 24. Pfizer Business Overview Table 25. Pfizer Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Pfizer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 27. Pfizer Recent Developments Table 28. GlaxoSmithKline Company Information Table 29. GlaxoSmithKline Business Overview Table 30. GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 32. GlaxoSmithKline Recent Developments Table 33. Bayer Company Information Table 34. Bayer Business Overview Table 35. Bayer Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Bayer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 37. Bayer Recent Developments Table 38. Synergy Pharmaceuticals Company Information Table 39. Synergy Pharmaceuticals Business Overview Table 40. Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 42. Synergy Pharmaceuticals Recent Developments Table 43. Sucampo Pharmaceuticals Company Information Table 44. Sucampo Pharmaceuticals Business Overview Table 45. Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 47. Sucampo Pharmaceuticals Recent Developments Table 48. Salix Pharmaceuticals Company Information Table 49. Salix Pharmaceuticals Business Overview Table 50. Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 52. Salix Pharmaceuticals Recent Developments Table 53. Roche Holding Company Information Table 54. Roche Holding Business Overview Table 55. Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 57. Roche Holding Recent Developments Table 58. Progenics Pharmaceuticals Company Information Table 59. Progenics Pharmaceuticals Business Overview Table 60. Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 62. Progenics Pharmaceuticals Recent Developments Table 63. Ironwood Pharmaceuticals Company Information Table 64. Ironwood Pharmaceuticals Business Overview Table 65. Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 67. Ironwood Pharmaceuticals Recent Developments Table 68. Ferring International Center Company Information Table 69. Ferring International Center Business Overview Table 70. Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 72. Ferring International Center Recent Developments Table 73. Chugai Pharmaceutical Company Information Table 74. Chugai Pharmaceutical Business Overview Table 75. Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 77. Chugai Pharmaceutical Recent Developments Table 78. Actavis Company Information Table 79. Actavis Business Overview Table 80. Actavis Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Actavis Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio Table 82. Actavis Recent Developments Table 83. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2021-2026) & (K Units) Table 85. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2021-2026) Table 86. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2027-2032) & (K Units) Table 87. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2027-2032) Table 88. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Region (2021-2026) Table 90. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Region (2027-2032) Table 92. North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026) & (K Units) Table 94. North America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032) & (K Units) Table 95. North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026) & (K Units) Table 99. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032) & (K Units) Table 100. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026) & (K Units) Table 109. South America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032) & (K Units) Table 110. South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2021-2026) & (K Units) Table 118. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2027-2032) & (K Units) Table 119. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2021-2026) Table 120. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2027-2032) Table 121. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2021-2026) Table 124. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2027-2032) Table 125. Global Chronic Idiopathic Constipation (CIC) Drugs Price by Type (2021-2026) & (US$/Unit) Table 126. Global Chronic Idiopathic Constipation (CIC) Drugs Price by Type (2027-2032) & (US$/Unit) Table 127. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2021-2026) & (K Units) Table 128. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2027-2032) & (K Units) Table 129. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2021-2026) Table 130. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2027-2032) Table 131. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2021-2026) Table 134. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2027-2032) Table 135. Global Chronic Idiopathic Constipation (CIC) Drugs Price by Application (2021-2026) & (US$/Unit) Table 136. Global Chronic Idiopathic Constipation (CIC) Drugs Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Chronic Idiopathic Constipation (CIC) Drugs Distributors List Table 140. Chronic Idiopathic Constipation (CIC) Drugs Customers List Table 141. Chronic Idiopathic Constipation (CIC) Drugs Industry Trends Table 142. Chronic Idiopathic Constipation (CIC) Drugs Industry Drivers Table 143. Chronic Idiopathic Constipation (CIC) Drugs Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Chronic Idiopathic Constipation (CIC) Drugs Product Image Figure 5. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Chronic Idiopathic Constipation (CIC) Drugs Sales (2021-2032) & (K Units) Figure 8. Global Chronic Idiopathic Constipation (CIC) Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Lubiprostone Product Image Figure 10. Linaclotide Product Image Figure 11. Others Product Image Figure 12. Ambulatory Surgical Centres Product Image Figure 13. Hospitals & Clinics Product Image Figure 14. Long Term Care Centres Product Image Figure 15. Others Product Image Figure 16. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Chronic Idiopathic Constipation (CIC) Drugs Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region in 2025 Figure 22. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region in 2025 Figure 23. North America Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country in 2025 Figure 24. North America Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2021-2032) Figure 25. North America Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Country (2021-2032) Figure 26. United States Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country in 2025 Figure 29. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2021-2032) Figure 30. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Country (2021-2032) Figure 31. Germany Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country in 2025 Figure 37. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Country (2021-2032) Figure 39. China Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country in 2025 Figure 48. South America Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2021-2032) Figure 49. South America Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Country (2021-2032) Figure 50. Mexico Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country in 2025 Figure 54. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Country (2021-2032) Figure 56. Turkey Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Chronic Idiopathic Constipation (CIC) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2021-2032) Figure 60. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2021-2032) Figure 61. Global Chronic Idiopathic Constipation (CIC) Drugs Price (US$/Unit) by Type (2021-2032) Figure 62. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2021-2032) Figure 63. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2021-2032) Figure 64. Global Chronic Idiopathic Constipation (CIC) Drugs Price (US$/Unit) by Application (2021-2032) Figure 65. Chronic Idiopathic Constipation (CIC) Drugs Value Chain Figure 66. Chronic Idiopathic Constipation (CIC) Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Chronic Idiopathic Constipation (CIC) Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Lubiprostone
  • Linaclotide
  • Others
Applications
  • Ambulatory Surgical Centres
  • Hospitals & Clinics
  • Long Term Care Centres
  • Others
Companies covered
  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Synergy Pharmaceuticals
  • Sucampo Pharmaceuticals
  • Salix Pharmaceuticals
  • Roche Holding
  • Progenics Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Ferring International Center
  • Chugai Pharmaceutical
  • Actavis

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size (2021-2032)
  4. 2.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales (2021-2032)
  5. 2.2.3 Global Chronic Idiopathic Constipation (CIC) Drugs Market Average Price (2021-2032)
  6. 2.3 Chronic Idiopathic Constipation (CIC) Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Lubiprostone
  9. 2.3.3 Linaclotide
  10. 2.3.4 Others
  11. 2.4 Chronic Idiopathic Constipation (CIC) Drugs by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Ambulatory Surgical Centres
  14. 2.4.3 Hospitals & Clinics
  15. 2.4.4 Long Term Care Centres
  16. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Chronic Idiopathic Constipation (CIC) Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Chronic Idiopathic Constipation (CIC) Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Established Date
  9. 3.9 Global Chronic Idiopathic Constipation (CIC) Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Pfizer
  8. 4.2.1 Pfizer Company Information
  9. 4.2.2 Pfizer Business Overview
  10. 4.2.3 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  12. 4.2.5 Pfizer Recent Developments
  13. 4.3 GlaxoSmithKline
  14. 4.3.1 GlaxoSmithKline Company Information
  15. 4.3.2 GlaxoSmithKline Business Overview
  16. 4.3.3 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  18. 4.3.5 GlaxoSmithKline Recent Developments
  19. 4.4 Bayer
  20. 4.4.1 Bayer Company Information
  21. 4.4.2 Bayer Business Overview
  22. 4.4.3 Bayer Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bayer Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  24. 4.4.5 Bayer Recent Developments
  25. 4.5 Synergy Pharmaceuticals
  26. 4.5.1 Synergy Pharmaceuticals Company Information
  27. 4.5.2 Synergy Pharmaceuticals Business Overview
  28. 4.5.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  30. 4.5.5 Synergy Pharmaceuticals Recent Developments
  31. 4.6 Sucampo Pharmaceuticals
  32. 4.6.1 Sucampo Pharmaceuticals Company Information
  33. 4.6.2 Sucampo Pharmaceuticals Business Overview
  34. 4.6.3 Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  36. 4.6.5 Sucampo Pharmaceuticals Recent Developments
  37. 4.7 Salix Pharmaceuticals
  38. 4.7.1 Salix Pharmaceuticals Company Information
  39. 4.7.2 Salix Pharmaceuticals Business Overview
  40. 4.7.3 Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  42. 4.7.5 Salix Pharmaceuticals Recent Developments
  43. 4.8 Roche Holding
  44. 4.8.1 Roche Holding Company Information
  45. 4.8.2 Roche Holding Business Overview
  46. 4.8.3 Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  48. 4.8.5 Roche Holding Recent Developments
  49. 4.9 Progenics Pharmaceuticals
  50. 4.9.1 Progenics Pharmaceuticals Company Information
  51. 4.9.2 Progenics Pharmaceuticals Business Overview
  52. 4.9.3 Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  54. 4.9.5 Progenics Pharmaceuticals Recent Developments
  55. 4.10 Ironwood Pharmaceuticals
  56. 4.10.1 Ironwood Pharmaceuticals Company Information
  57. 4.10.2 Ironwood Pharmaceuticals Business Overview
  58. 4.10.3 Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  60. 4.10.5 Ironwood Pharmaceuticals Recent Developments
  61. 4.11 Ferring International Center
  62. 4.11.1 Ferring International Center Company Information
  63. 4.11.2 Ferring International Center Business Overview
  64. 4.11.3 Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  66. 4.11.5 Ferring International Center Recent Developments
  67. 4.12 Chugai Pharmaceutical
  68. 4.12.1 Chugai Pharmaceutical Company Information
  69. 4.12.2 Chugai Pharmaceutical Business Overview
  70. 4.12.3 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  72. 4.12.5 Chugai Pharmaceutical Recent Developments
  73. 4.13 Actavis
  74. 4.13.1 Actavis Company Information
  75. 4.13.2 Actavis Business Overview
  76. 4.13.3 Actavis Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Actavis Chronic Idiopathic Constipation (CIC) Drugs Product Portfolio
  78. 4.13.5 Actavis Recent Developments
5 Global Chronic Idiopathic Constipation (CIC) Drugs Market Scenario by Region
  1. 5.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region: 2027-2032
  5. 5.3 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Chronic Idiopathic Constipation (CIC) Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Chronic Idiopathic Constipation (CIC) Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Chronic Idiopathic Constipation (CIC) Drugs Market Facts & Figures by Country
  35. 5.7.1 South America Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2032)
  37. 5.7.3 South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Chronic Idiopathic Constipation (CIC) Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Chronic Idiopathic Constipation (CIC) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Chronic Idiopathic Constipation (CIC) Drugs Value Chain Analysis
  2. 8.1.1 Chronic Idiopathic Constipation (CIC) Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Chronic Idiopathic Constipation (CIC) Drugs Production Mode & Process
  5. 8.2 Chronic Idiopathic Constipation (CIC) Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Chronic Idiopathic Constipation (CIC) Drugs Distributors
  8. 8.2.3 Chronic Idiopathic Constipation (CIC) Drugs Customers
9 Global Chronic Idiopathic Constipation (CIC) Drugs Analyzing Market Dynamics
  1. 9.1 Chronic Idiopathic Constipation (CIC) Drugs Industry Trends
  2. 9.2 Chronic Idiopathic Constipation (CIC) Drugs Industry Drivers
  3. 9.3 Chronic Idiopathic Constipation (CIC) Drugs Industry Opportunities and Challenges
  4. 9.4 Chronic Idiopathic Constipation (CIC) Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.